Key result
Veterinary cardiologists and clinicians often prescribe treatments for feline hypertrophic cardiomyopathy despite acknowledging a lack of published clinical evidence supporting their decisions.
Cross-Sectional (n=98)
Randomized to survey groups A or B
Veterinary cardiologists frequently base treatment decisions for feline hypertrophic cardiomyopathy on theoretical benefits or personal experience due to a profound lack of robust clinical evidence.
Answers are grounded in this paper and cite their sources.
Emphasizes evidence gaps in feline HCM care; leaves open treatment efficacy and prioritizes randomized trials before practice change.
PRACTICAL RELEVANCE: Feline hypertrophic cardiomyopathy (HCM) is the most common cardiac disease of cats. Treatment of HCM is usually directed at controlling signs of congestive heart failure (CHF), preventing occurrence or recurrence of systemic thromboembolism or delaying/preventing/reversing progression of subclinical disease. STUDY OBJECTIVE AND DESIGN: Despite the laudable goals of therapy, however, little objective evidence supporting therapeutic decisions has been published. We, therefore, hypothesized that cardiologists base their treatment strategies on information other than published clinically relevant science. To gain insight into therapeutic decisions that cardiologists and clinicians with an interest in cardiology (n=99) make for cats with HCM, and on what information they base these decisions, we presented participants with, and asked them to select therapy for, 12 hypothetical scenarios of HCM (± CHF). Responses and justifications for treatment choices were compiled and compared with the results of a comprehensive literature search for published information about treatment of feline HCM. FINDINGS: Evaluation of the therapeutic strategies chosen for these hypothetical cases of HCM suggests that cardiologists or clinicians with a strong interest in cardiology often prescribe treatments knowing that little documented evidence supports their decisions.
No takes yet. Share an insight, caveat, or question.
Rishniw et al. (2011) conducted a cross-sectional in Feline hypertrophic cardiomyopathy (n=98). Hypothetical clinical scenarios of feline HCM was evaluated on Therapeutic strategies chosen for hypothetical cases of HCM and justifications for treatment choices. Veterinary cardiologists and clinicians often prescribe treatments for feline hypertrophic cardiomyopathy despite acknowledging a lack of published clinical evidence supporting their decisions.
Synapse has enriched 10 related papers. Consider them for comparative context: